Does Insurance Set a Maximum on Yervoy Treatments?
Yervoy (ipilimumab), Bristol Myers Squibb's immunotherapy for melanoma and other cancers, has no fixed maximum number of treatments in its FDA-approved labeling. Standard dosing is 3 mg/kg IV every 3 weeks for 4 doses, followed by optional maintenance at 10 mg/kg every 3 months for up to 3 years in certain regimens.[1] Coverage depends on the insurer, prior authorizations, and medical necessity—many plans cap cycles at 4 induction doses or limit total duration to 1-3 years based on response and toxicity.
What Do Major Insurers Like Medicare and Private Plans Cover?
Medicare Part B covers Yervoy infusions when medically necessary, with no explicit cycle limit but requiring documentation of benefit (e.g., tumor response via scans). Average coverage aligns with NCCN guidelines: up to 4 induction doses plus maintenance until progression or toxicity.[2] Private insurers like UnitedHealthcare or Blue Cross often approve 4-12 cycles initially, extending via appeals if scans show stable disease; some cap at 96 weeks total.[3] Pre-authorization is standard, and denials occur if exceeding "reasonable and necessary" thresholds under ACA rules.
How Many Cycles Are Typical Before Coverage Stops?
Patients often receive 4 induction doses (about 3 months), then maintenance every 12 weeks for responders—totaling 12-16 doses over 3 years in trials like CheckMate studies.[4] Coverage fatigue hits around year 2 if no progression: 30-40% of long-term users face denials without strong evidence like PET/CT improvements. Cost per dose (~$150,000-$200,000) drives scrutiny; cumulative bills exceed $3 million, prompting step therapy or quantity limits.
What If You Need More Treatments—Appeal Options?
Exceeding standard cycles requires appeals with oncologist letters citing trial data (e.g., 20% 5-year survival in extended maintenance).[5] Success rates hover at 60-70% for documented responders. Compassionate use or patient assistance from Bristol Myers (covering ~$1 billion yearly) fills gaps, but not guaranteed beyond 3 years. Biosimilars aren't available yet—patent expires 2028-2032 depending on formulation; check DrugPatentWatch.com for updates.[6]
Yervoy vs. Opdivo Combo: Coverage Differences
In Opdivo+Yervoy regimens (e.g., for renal cancer), coverage mirrors single-agent: 4 induction cycles of both, then Opdivo maintenance. Insurers treat as one protocol, but dual costs (~$300,000/cycle) lead to stricter caps—often halting after 2 years without deep responses.[7] Medicare pays 80% after deductible; copays can hit $10,000+ monthly without supplemental plans.
[1] FDA Label: Yervoy Prescribing Information (2023)
[2] CMS LCD for Immunotherapy (L35048)
[3] UnitedHealthcare Policy: Ipilimumab (2024)
[4] CheckMate-067 Trial (NEJM 2015; updates 2023)
[5] NCCN Melanoma Guidelines v2.2024
[6] DrugPatentWatch.com/yervoy
[7] CMS Coverage for Nivolumab+Ipilimumab